Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · April 22, 2024

Efficacy and Safety of Giredestrant Therapy in Patients With Previously Treated ER+, HER2− Advanced Breast Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study
J. Clin. Oncol 2024 Mar 27;[EPub Ahead of Print], M Martín, E Lim, M Chavez-MacGregor, A Bardia, J Wu, Q Zhang, Z Nowecki, FM Cruz, R Safin, SB Kim, C Schem, AJ Montero, S Khan, R Bandyopadhyay, HM Moore, M Shivhare, M Patre, J Martinalbo, L Roncoroni, PD Pérez-Moreno, J Sohn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading